To access this element change to forms mode OFF
Grant Award View - GA166497
I-124 PET Directed Redifferentiation Therapy for Radioiodine Refractory...
GA ID:
GA166497
Agency:
Department of Health and Aged Care
Approval Date:
17-Apr-2021
Publish Date:
25-May-2021
Category:
Health and Medical Research
Grant Term:
1-Jun-2021 to 31-May-2026
Value (AUD):
$2,708,660.70
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 20/21 1.1 Health Policy Research and Analysis
Grant Program:
2020_MRFF_RCRDUN_RCRDUN_2021_General
Grant Activity:
I-124 PET Directed Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer: the I-FIRST Study
Purpose:
While current treatments for thyroid cancer are usually effective, a subset of patients will stop responding or become less sensitive to I-131 treatment. The outcome for these patients is poor, and further treatment options may not be effective or have significant toxicity. This prospective multicentre trial will use cutting edge imaging to evaluate the ability of drugs to 'resensitize' the tumour to I-131 therapy. We will also determine the affordability of bringing this therapy to the clinic.
GO ID:
GO Title:
MRFF Clinical Trials Activity Initiative – 2020 Rare Cancers, Rare Diseases and Unmet Need General Grant Opportunity
Internal Reference ID:
MRF2006511
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
La Trobe University
Recipient ABN:
64 804 735 113
Grant Recipient Location
Suburb:
Bundoora
Town/City:
Bundoora
Postcode:
3083
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, WA, QLD
Postcode:
Multiple
Country:
AUSTRALIA